AOD-9604 vs CJC-1295: Research Literature Comparison
The practical distance between AOD-9604 and CJC-1295 shows up first in how much published methodology exists for each.
Compound profiles
AOD-9604 in the indexed record
The literature on AOD-9604 is a limited body of work: 16 PubMed-indexed records with no registered studies currently listed on ClinicalTrials.gov.
Recent indexed work appears in Curr Opin Investig Drugs, Drug Test Anal, Expert Rev Proteomics, spanning 2004–2026.
- AOD-9604 Metabolic — Curr Opin Investig Drugs, 2004. PMID: 15134286
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — J Am Acad Orthop Surg Glob Res Rev, 2026. PMID: 41490200
- AOD-9604 does not influence the WADA hGH isoform immunoassay — Drug Test Anal, 2013. PMID: 24124033
- Human sports drug testing by mass spectrometry — Mass Spectrom Rev, 2017. PMID: 26213263
CJC-1295 in the indexed record
Indexed output for CJC-1295 stands at 33 records, a limited literature, alongside 1 registered studies on ClinicalTrials.gov.
Journals represented in the current index include Am J Sports Med, Growth Horm IGF Res, J Am Acad Orthop Surg Glob Res Rev, spanning 2006–2026.
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults — J Clin Endocrinol Metab, 2006. PMID: 16352683
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians — Am J Sports Med, 2026. PMID: 41476424
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — J Am Acad Orthop Surg Glob Res Rev, 2026. PMID: 41490200
- Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions — Subst Use Misuse, 2016. PMID: 26771670
How the literature differs
The indexed record is not symmetrical between these two compounds. CJC-1295 carries 17 more indexed records than AOD-9604, which means published methodology, characterisation data and replication attempts are more readily located for CJC-1295. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (0 vs 1) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Side-by-side research profile
| Parameter | AOD-9604 | CJC-1295 |
|---|---|---|
| PubMed indexed records | 16 | 33 |
| Registered studies (ClinicalTrials.gov) | 0 | 1 |
| Literature depth | Emerging | Emerging |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
Classification and why it matters
AOD-9604 and CJC-1295 sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for AOD-9604 describes conditions validated for AOD-9604: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to CJC-1295 without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
Laboratory handling
Both compounds ship as lyophilised powder. Convention is storage of the sealed vial at -20°C away from light, with reconstitution immediately before experimental use. In solution, peptides are materially less stable than in lyophilised form.
Freeze-thaw cycling degrades integrity; aliquoting after reconstitution avoids repeatedly cycling one vial.
Verification and documentation
What is in the vial is established by lot-specific analytics, not by label text. HPLC gives purity as a share of total peak area; mass spectrometry confirms the molecular weight matches the intended sequence. Neither substitutes for the other.
Selecting between them for a study design
AOD-9604 and CJC-1295 are not interchangeable. They differ in structural class and in the pathways the literature associates with each, so substituting one for the other changes what a model is actually measuring.
Where a protocol cites a specific compound, the cited compound is the one the published result applies to. Where no protocol exists, the compound with the deeper indexed record (CJC-1295) generally offers more methodological precedent.
Frequently asked questions
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
Which of AOD-9604 or CJC-1295 has more published research?
CJC-1295, with 33 indexed PubMed records against 16.
How should these compounds be stored?
Lyophilised material is conventionally stored at -20°C protected from light. Reconstituted solution is far less stable and is held at 2-8°C for short-duration laboratory work only.
Related references
- AOD-9604 — product and lot documentation
- CJC-1295 — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.